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‘I don’t think I’d be frightened if the statins
went’: a phenomenological qualitative
study exploring medicines use in palliative
care patients, carers and healthcare
professionals.
Adam Todd1*, Holly Holmes2, Sallie Pearson3, Carmel Hughes4, Inga Andrew5, Lisa Baker5 and Andy Husband1
Abstract
Background: There is a growing body of evidence suggesting patients with life-limiting illness use medicines
inappropriately and unnecessarily. In this context, the perspective of patients, their carers and the healthcare
professionals responsible for prescribing and monitoring their medication is important for developing deprescribing
strategies. The aim of this study was to explore the lived experience of patients, carers and healthcare professionals
in the context of medication use in life-limiting illness.
Methods: In-depth interviews, using a phenomenological approach: methods of transcendental phenomenology
were used for the patient and carer interviews, while hermeneutic phenomenology was used for the healthcare
professional interviews.
Results: The study highlighted that medication formed a significant part of a patient’s day-to-day routine; this was also
apparent for their carers who took on an active role-as a gatekeeper of care-in managing medication. Patients described
the experience of a point in which, in their disease journey, they placed less importance on taking certain medications;
healthcare professionals also recognize this and refer it as a ‘transition’. This point appeared to occur when the patient
became accepting of their illness and associated life expectancy. There was also willingness by patients, carers and
healthcare professionals to review and alter the medication used by patients in the context of life-limiting illness.
Conclusions: There is a need to develop deprescribing strategies for patients with life-limiting illness. Such strategies
should seek to establish patient expectations, consider the timing of the discussion about ceasing treatment and
encourage the involvement of other stakeholders in the decision-making progress.
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Background
Improving care for people with life-limiting illness is an
international priority [1]. Due to aging populations, and
the increasing proportion of the population with
advanced illness at the end of life, palliative care is a
major public health issue and forms a key part of our
society [2]. One important component of this agenda-
given that many patients with advanced illness have
other complex, co-morbid conditions-is ensuring their
pharmacotherapy is appropriate, safe and rational. There
is, however, growing evidence suggesting patients with
life-limiting illness use an excess number of medications,
many of which are inappropriate and unnecessary-this
contributes to a high pill burden for the patient and, in
some cases, has significant safety implications [3–7]. In
view of this, there is a movement towards developing
‘deprescribing’ approaches for these patients, that is the
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process of reducing or discontinuing drugs, aimed at
minimizing polypharmacy and improving patient outcomes.
For example, Scott and colleagues have developed a five
step deprescribing protocol that considers, amongst other
things, indication of the medication; the benefit-harm ratio
and the potential harm or burden of future treatment [8].
Lindsay and colleagues have taken a different approach and
produced a deprescribing guideline suitable for use in
palliative cancer patients; [9] this is a defined list of medica-
tions (or classes of medication) that could be suitable for
stopping in this population (e.g. the use of aspirin for
primary prevention of cardiovascular disease). However,
despite these approaches, patients continue to be pre-
scribed medication unnecessarily and inappropriately-the
reasons for which are unclear. To take a holistic approach
to developing deprescribing strategies, it is important to
understand the perspective of patients, their carers and the
healthcare professionals responsible for prescribing their
medication-something which current strategies fail to do.
Unfortunately, there is a scarcity of literature in this area
and little is known about how these groups experience
pharmacological care in the context of life-limiting illness.
This study, therefore, aimed to explore the lived experience
of patients, carers and healthcare professionals in the
context of medication use in life-limiting illness.
Method
Recruitment and sampling
Patients attending a day care centre at a specialist
palliative care unit based within the North of England
were invited to take part in the study. The day care
centre is a small, modern purpose built facility; it accom-
modates around ten patients in any one time and offers
clinical outpatient services, as well as providing social
activities for patients. The average life expectancy of
patients attending the day care centre was approximately
18 months. To be included in the study, patients and
carers had to be over 18 years of age and healthcare
professionals had to be responsible for prescribing medi-
cation to this general patient group. Carers were identified
and approached through patients attending the day care
centre. For the purposes of the study, a carer was defined
as a friend or family member supporting the needs of a
patient with life-limiting illness. Carers employed by the
National Health Service (NHS) or charities in that
capacity were excluded from the study. A purposive
sampling framework was used to ensure there was
maximum variation in gender, age and type of life limit-
ing illness for the patient and carer participants and by
type of practitioner for the healthcare professional par-
ticipants. Recruitment ended once theoretical data sat-
uration was reached, i.e. when no new themes emerged,
across the three constituent groups, as assessed by two
researchers (AT and AH).
Methodological approach
In-depth interviews, using a phenomenological approach,
were used to explore the ‘lived experiences’ of patients and
their carers, as well as those healthcare professionals who
are involved in prescribing and monitoring medication for
patients with life-limiting illness. Methods of transcendental
phenomenology [10] were used for the patient and carer
interviews to explore experiences of medication use; i.e.
‘what’ was experienced, as well as the way in which care
was provided i.e. ‘how’ medication use was experienced.
Transcendental phenomenology is focused on describing
experiences through the eyes of participants, rather than
presenting interpretative representations. Accordingly, any
prior beliefs or knowledge about medication use for this
group were ‘bracketed’ by the interviewer, enabling the
accounts of patients and carers to be told without influence,
thus appearing fresh. Given the complexities of prescribing
medication to patients with life-limiting illness, and the
need for healthcare professionals to engage in evidence-
based care, methods of hermeneutic (or existential) phe-
nomenology [11] were used for these interviews. Hermen-
eutic phenomenology focuses upon the interpretation of an
experience; the methodology recognizes the context within
which experiences take place and uses this to better under-
stand the lived experience. Hermeneutic phenomenology is
appropriate in this context, as it allows for subtle interpre-
tations and allows for discussions about evidence-based
practice set against the realities of day-to-day care. Given
the hermeneutic phenomenological approach to these in-
terviews, they were informed by the previous interviews
with patients and carers.
Interviews with patients were conducted in a specialist
palliative care unit within an outpatient setting; interviews
with carers were conducted in their own home, while in-
terviews with healthcare professionals were conducted in
their place of work. The interviews for patients and carers
were undertaken separately.
During the interview, participants were asked three
open-ended questions:
 What is a normal day like for you?
 What are your experiences of medication use (from the
perspective of a patient/carer/healthcare professional)?
 Is there any desire for change?
Each question was followed up with probing questions to
explore the participants’ lived experience. Towards the end
of each interview, an image of multiple medications was
shown to participants to help understand their experiences
(Fig. 1). This technique, known as photo elicitation, is a
recognized method in qualitative research [12] and can
elicit more information from the participant, as parts of the
brain that process visual information are older in evolution-
ary terms than parts that process verbal information [13].
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Data analysis
Interviews were recorded, transcribed and analyzed verba-
tim by two researchers (AT and AH) using thematic
analysis with the following stages: familiarization with the
data by re-reading transcripts; identification of significant
phrases that pertained to the experience; formulating
meaning of the phrases and clustering those themes com-
mon to all of the transcripts; integrating the themes into
an in-depth, exhaustive description of the phenomenon
[14]. Any discrepancies were resolved through discussion
(AT, AH) and if agreement was not reached, by consensus
(IA). Emergent themes were tested using diverse accounts
between cases, in order to challenge the integrity of the
boundaries of themes. Data analysis produced a textural
description of ‘what’ the participants experienced and
expected, as well as a structural description of ‘how’ they
experienced pharmacological care: the combination of the
two conveyed their overall experience. When using direct
quotes from patients and carers, pseudonyms were given
to ensure confidentiality.
Ethical approval
The study complied with the 2013 Declaration of
Helsinki; ethical approval was obtained from Durham
University (reference ESC2/2013/17). All participants
provided written informed consent prior to participating
in the study.
Results
Thirty-six participants in total were recruited to the study:
12 for each group. The characteristics for each patient are
described in Table 1; for the healthcare professional in-
terviews, three palliative medicine consultants, three ad-
vanced nurse practitioners and six general practitioners
(GPs) were recruited. All of the carers recruited to the
study were family members of the patient. From the inter-
views, themes specifically emerged around medication
use, which fell into three main categories: medication as
part of daily routine; risks of medication; and, willingness
to change.
Medication forms part of daily routine
The majority of patient and carer participants specific-
ally referred to medication when asked to describe what
a normal day was like for them. Many patient partici-
pants described the daily routine of organizing and
taking the medication, while carers often referred to
organizing patients’ medication, including following-up
medication-related changes with the GP. One patient
used the term ‘habit’ to describe their experience of tak-
ing medication. Carers described acting as gatekeepers
in this context: they felt compelled to take ownership
and responsibility for managing patients’ medication.
Well, on a Saturday morning it’s the drug day. And
I’m in the kitchen for half-an-hour with all the boxes
and, you know. I go through the medication, put them
in the boxes and I’m checking to see if we need any,
and if we need any I have the reserve supply elsewhere
in the dining room, and I’ll go and get them from
there. Dorothy, carer.
When describing their medication regimen, several
patients revealed they did not know what particular
medications they used, or the indications for the medica-
tion. This knowledge was not important to patients, as
they had complete trust in the healthcare professionals
responsible for their care.
Well doctor says to me you take that tablet, that
tablet, that tablet, end of story. What the man says,
you take. There’s no good saying why, that one’s for
Fig. 1 The image shown to participants during the interview
Table 1 Patient participant characteristics
Participant
number
Gender Age range
in years
Life limiting illness
1 Male 51–60 Lung Cancer
2 Female 61–70 Liver Cancer
3 Male 61–70 Parkinson’s Disease
4 Male 71–79 Prostate Cancer
5 Male 61–70 Prostate Cancer
6 Female 71–79 COPD
7 Male 51–60 Prostate Cancer
8 Male <50 Motor Neurone Disease
9 Female 51–60 Colorectal Cancer
10 Female 71–79 Renal Cancer
11 Female ≥80 Heart failure
12 Male ≥80 COPD
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your liver, that one’s for your heart and that one’s for
your whatever, and stuff like that. Just take them and
Bob’s your uncle. Donald, Parkinson’s disease patient
This lack of understanding was not experienced by
carers, who had a good knowledge and understand-
ing of the patient’s medication; this appeared to stem
from the feeling of having responsibility for the pa-
tients’ medication.
When responding to the photograph of multiple medi-
cations, healthcare professionals stated that the image
was very familiar and, although they were dismayed by
it, it was acknowledged that the challenges associated
with taking multiple medications were part of their daily
routine when managing patients with life limiting illness.
Familiarity! Absolutely total and utter confusion and
a huge risk for error all along the way for the patient-
how on earth the patient gets his head round taking,
or her head round taking all of that lot, I really have
no idea, and that’s something I’ve been very aware of
when I’ve been out to homes. General Practitioner 6
Risk of medication
The majority of patients described experiencing adverse
effects from taking their medications; this appeared to
form a significant part of the overall experience of using
medications. It was also acknowledged by participants
that no medication was fully ‘safe’ and entirely free from
risk. The adverse effects described by patients were from
a mixture of medication types, including those that were
disease-modifying (e.g. chemotherapy), or medications
used to treat or prevent long-term condition (e.g. anti-
hypertensives). Patients also felt as though the perceived
risk and benefits of taking specific medication changed,
depending on where they were within the journey of
their disease: a state of anxiety was described until a
specific point in the journey was reached. This point was
described after the patient was diagnosed with life-
limiting illness and appeared to occur when the patient
was accepting of their disease.
Well, I used to have high blood pressure, hypertension.
I used to check my blood pressure every day and
religiously take my tablets. And I thought eh, and I
would say it is higher than yesterday, and this used to
worry me. Now I don’t worry about it; I don’t even
check-I still take my blood pressure tablets-but not
religiously like I used to. It’s not so important. Martha,
liver cancer patient
Healthcare professionals also described experiencing
this change where patients placed less importance on
certain medications. Such a phenomenon was referred
to as a ‘transition’ in which it was acknowledged that
patients placed less importance on certain medications.
This term was analogous to the experience described by
patients, where anxiety was described until a specific
point in the treatment journey was reached. In some
cases, healthcare professionals appeared to respond to
this state and modified their treatment approach to
account for this.
Apart from a tiny percentage of people who perhaps have
an unrealistic expectation about what the medication
can do, and my experience of patients dealing with, you
know, patients in palliative care is that most transition
beautifully, most can do it, most don’t worry about it.
Palliative Medicine Consultant (3)
Patients perceived that not all medication was the
same and placed different values and beliefs on them
in terms of their risk and benefit. These values and
beliefs were not consistent and varied between types
of medication. The experience of taking statins was
often described:
I was put on a statin and I didn’t like it. It was giving
me physical side effects. I wanted to stop my statin but
I thought I’d be committing suicide – I know it’s
important for my heart. William, prostate cancer
I don’t think I’d be frightened if the statins went. And I
think the medical profession as well often make
mistakes about good cholesterol and bad cholesterol.
You know, some cholesterol is actually good for you
and I think too many doctors, just say on a high
cholesterol reading, terrible, get out the statins.
George, prostate cancer
Willingness to change medication
Across all participant groups, there was an acknowledge-
ment that medications were burdensome interventions
and there was a willingness to rationalize them in this
context. This was particularly the case where treatment
regimens had a high pill burden. In many cases, patients
were not concerned with the type of the medication they
were taking, but were overwhelmed by the volume of it-
one patient described this experience as ‘disgusting’. This
was further exacerbated when patients had difficulty in
swallowing medication.
I cannot swallow them, you know if they’re coated, like a
Smartie, I’m okay, but if they’re not coated I cannot
them, cannot get them down. So when it like sort of
melts in your mouth that’s when I feel sick. And I’ll say
oh I’m not taking them. I’m always changing, telling the
doctors like. Annie, heart failure patient
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In this context, the acknowledgement by participants
that medications were burdensome, both in terms of
volume and type appeared to act as an impetus for want-
ing change. Carers would embrace deprescribing ap-
proaches, providing the risks and benefits were properly
explained and it was done for the benefit of the patient.
If stopping the tablets are for her benefit then I’m
happy with that. But if I thought it was for costs or
anything like that, or trying to make the books budget
I wouldn’t be happy with that at all. Jenny, carer
Given the complexity of care for patients with life-
limiting illness, healthcare professionals found commu-
nicating with each other frustrating and this was ac-
knowledged as a barrier to change; this challenge was
particularly evident for the interfaces between primary,
secondary and tertiary care. The importance of coming
to a joint decision between healthcare professional, pa-
tient and carer was perceived as important by all partici-
pants when considering deprescribing medication.
I’ve had GPs that I’ve stopped statins and then they’ve
been restarted and I haven’t known if it’s because it’s
on the repeat prescription and they haven’t stopped it,
and then that’s me back on the phone-can you stop the
statin. Palliative Care Consultant 1
Despite these challenges, all of the participants did,
however, have experience of-in terms of giving, observ-
ing or receiving-a deprescribing event. In some cases,
when medication was initiated, patients were told that
they would be taking it ‘for the rest of their life’; this was
literally interpreted by patients that they would be taking
the medication until the day they died. The experience
of being told this appeared to be a significant barrier to
deprescribing approaches, as it created a mismatch of
expectations between healthcare professional and patient
and carer regarding treatment.
I did used to take blood pressure tablets atenolol and
lisinopril, and was told by the GP I used to see oh
you’ll be on these for the rest of your life. And my
current GP, she’s looked at it said, oh I am going to
take you off the blood pressure tablets. I wasn’t scared
but I was surprised. George, prostate cancer patient
In some cases, when instigating a deprescribing event,
the healthcare professional was required to have discussions
with patient and carer, regarding treatment expectations
and disease trajectory. Several healthcare professionals
described discussions of this nature as ‘difficult’ and
considered that appropriate timing of these discussions
was crucial.
Discussion
This is the first study to describe the lived experience of
patients, carers and healthcare professionals in the context
of medication use in life limiting illness. The study
highlighted that medication formed a significant part of a
patient’s day-to-day routine; this was also apparent for
their carers who took on an active role-as a gatekeeper of
care-in managing medication. Patients also described a
phenomenon of experiencing anxiety until a specific point
in the treatment journey was reached, while healthcare
professionals also recognized this and described it as a
‘transition’ where the patient places less importance on
taking certain medications. This phenomenon was de-
scribed after the patient was diagnosed with a life-limiting
illness and appeared to occur once the patient became
accepting of their illness and associated life expectancy.
The medications associated with this ‘transition’ were
typically used to treat or prevent long-term conditions
and had been taken chronically by patients for a number
of years. There was also willingness by all participants to
change the amount of medication that was used in the
context of life-limiting illness; this change was related to
the type of medication but, more importantly, for many
patients, the pill burden.
There have been several other studies exploring the
perceptions of patients with diminished life expectancy
regarding medication [15–18]. Of note, Sand and col-
leagues [16] explored medication use in a group of
patients with advanced cancer, and showed there was a
desire to reduce the number of tablets they took, as the
medication reminded them of their illness, while Qi and
colleagues [17] showed the majority of older people were
accepting of having one of their medications deprescribed.
Tjia and colleague [19] assessed the applicability of a con-
ceptual carer medication management skills framework
[20], by analyzing home hospice visits between a nurse,
patient and carer. The themes that emerged in this
work-such as medication knowledge and discontinuing
medications-were similar to what is reported in our
sample of participants, which lends support to our
findings.
In terms of implications for policy, many patients in our
study described positive experiences of deprescribing-
particularly with regards to medication used to treat or pre-
vent long-term conditions. The finding is timely given a
recent randomized trial on statin discontinuation which
has shown that stopping statins in patients with anticipated
life expectancy from one month to one year did not
adversely affect patient outcomes and indeed, patients who
stopped statins had a better quality of life [21]. Our work
shows that when approaching a deprescribing intervention
for a patient with life-limiting illness, a number of critical
points should be considered. Firstly, establishing the patient
expectations of their medication, as some patients may
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believe that they will be taking specific medication until the
day they die. This has recently been highlighted in a set of
recommendations to support deprescribing approaches in
life-limiting illness [22]. The second factor is the timing of
the discussion regarding a deprescribing event, which is
important, as our work shows there is a transition in which
a patient places less importance on taking certain medica-
tion. Discussing a deprescribing intervention with a patient
who has not yet reached this point is likely to result in a
poor outcome. The third factor that appears to be import-
ant is encouraging the involvement of other stakeholders in
the decision-making process, as carers (such as family
members) also have an active involvement in the ma-
nagement of medication. These critical points should be
considered in any wider approach to developing future
deprescribing interventions in this population. It is in-
teresting to note that current deprescribing approaches
directed towards this population do not appear to consider
these critical points.
Good communication between healthcare professionals
enabling good information transfer was also considered im-
portant when deprescribing medication-something which
has been acknowledged [23]. Previous qualitative work has
shown that GPs were anxious about discontinuing pre-
ventative medication in very old patients, as they worried
patients may have interpreted this as a sign of being
‘abandoned’ [24]. Importantly, our work does not
support this, but instead shows that deprescribing
medication-or broaching the subject of deprescribing
medication-does not appear to affect the hope of
patient in terms of their illness.
While we believe our results are robust and have
important implications for the way in which medication
is prescribed to patients with life-limiting illness, we do
acknowledge that the research was predominantly fo-
cused on a small sample of people in the North of
England. We did not assess or sample patient or carer
participants by socioeconomic status or ethnicity. It is
possible that participants with different ethnicities or
different socioeconomic classes may have different expe-
riences of using medication in the context of life limiting
illness. Our results should therefore be interpreted with
this in mind. Given the role as carers as gatekeepers of
healthcare, and that few studies have explored the
experience of carers alongside patients and healthcare
professionals, we acknowledge this as a key strength of
our study. As part of our methodology, we interviewed
patients and carers separately to ensure a true descrip-
tion of their lived experience was obtained; interviewing
patients and carers together may elicit different re-
sponses and this could be an avenue for future research.
Our methodological approach also had strengths and
weaknesses: as part of our interview, we showed
participants-as a method of photo elicitation-an image
of medications. This approach strengthens this study, as
images tend to evoke deeper elements of the human
conscious than words and accordingly can yield more
descriptive data. In terms of weaknesses, while phenom-
enology has been successfully employed as a method-
ology to improve understanding of the experience of
illness [25–27], we do acknowledge that this method
requires participants to describe the nature of their
experience. Several patient participants struggled to do
this and instead provided a narrative of their illness,
rather than focus on the experience of it.
Conclusion
There is willingness-from the lived experience of pa-
tients, carers and healthcare professionals-to change
the amount of medication used by patients in the con-
text of life-limiting illness. There is, therefore, a need to
develop deprescribing strategies for patients with life-
limiting illness. Such strategies should seek to establish
patient expectations of medication, consider the timing
of the discussion, and encourage the involvement of
other stakeholders in the decision-making progress.
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